Navigation Links
ERT Reports First Quarter 2011 Operating Results
Date:5/2/2011

PHILADELPHIA, May 2, 2011 /PRNewswire/ -- eResearchTechnology, Inc. (ERT), (Nasdaq: ERT) a global technology-driven provider of  services and customizable medical devices to biopharmaceutical and healthcare organizations and the market leader for centralized cardiac safety and respiratory efficacy services in drug development, announced today results for the first quarter ended March 31, 2011.  Unless otherwise noted, all comparative numbers refer to changes from the same period a year ago.  The financial results include the results related to CareFusion Research Services (RS) commencing from its date of acquisition on May 28, 2010.

This press release contains financial measures prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and non-GAAP measures adjusted to exclude the impact of the amortization of the acquired intangibles and other assets and acquisition and other costs related to the RS acquisition and related income tax effects.  A reconciliation of these GAAP and non-GAAP measures is found in the attached "Reconciliation of GAAP to Non-GAAP Information."

Financial Highlights for the First Quarter of 2011

  • Net revenues were $41.7 million for the first quarter of 2011 compared to $44.9 million for the fourth quarter of 2010 and $21.9 million a year ago.  Revenues from RS were $18.9 million in the first quarter of 2011, compared to $20.0 million in the fourth quarter of 2010.

  • GAAP gross margin percentage was 44.2% in the first quarter of 2011 compared to 43.9% for the fourth quarter of 2010 and 53.8% a year ago.  Non-GAAP gross margin percentage was 48.7% in the first quarter of 2011 compared to 49.0% for the fourth quarter of 2010 and 53.8% a year ago.  

  • GAAP operating income margin percentage was 12.8% in the first quarter of 2011 compared to 11.6% for the fourth quarter of 2010 and 12.6% a year ago.  Non-GAAP operating income margin percentage was 17.3% in the first quarter of 2011 compared to 18.5% for the fourth quarter of 2010 and 16.0% a year ago.

  • GAAP net income was $3.1 million, or $0.06 per diluted share, in the first quarter of 2011 compared to $4.1 million, or $0.08 per diluted share, in the fourth quarter of 2010 and $1.8 million, or $0.04 per diluted share, a year ago.  Non-GAAP net income was $4.5 million, or $0.09 per diluted share, in the first quarter of 2011 compared to $6.1 million, or $0.12 per diluted share, in the fourth quarter of 2010 and $2.2 million, or $0.05 per diluted share, a year ago.

  • Cash flow from operations was $5.0 million in the first quarter of 2011, compared to $17.1 million in the fourth quarter of 2010 and $5.3 million a year ago.

  • Cash and short-term investments totaled $29.7 million at March 31, 2011 compared to $30.4 million on December 31, 2010.  ERT had $21.0 million in long-term debt as of March 31, 2011 and December 31, 2010.

  • New bookings were $71.8 million in the first quarter of 2011 compared to $58.9 million for the fourth quarter of 2010 and $43.3 million a year ago.  

  • The gross book-to-bill ratio was 1.7 in the first quarter of 2011 compared to 1.3 in the fourth quarter of 2010 and 2.0 a year ago.  

  • Backlog was $318.6 million as of March 31, 2011 compared to $302.9 million as of December 31, 2010 and $182.7 million a year ago (which did not include RS).  The annualized cancellation rate was 24.6% in the first quarter of 2011 compared to 16.6% in the fourth quarter of 2010 and 21.3% a year ago.  

  • "We are very pleased with the record $71.8 million of bookings reported in this quarter," commented Dr. Joel Morganroth.  "This was driven by strong bookings using our integrated solution, which combines respiratory, cardiac safety, and ePRO to our customers.  Our revenue level was slightly lower than expected due to a large TQT cancellation during the quarter.  We also experienced higher cancellations in our respiratory business as three large studies were terminated by the sponsors.  We managed to moderate our expenses as some of the 2011 planned hiring and other investments were delayed.  Offsetting this was the negative impact of the foreign exchange rate changes, which resulted in a charge of approximately $0.01 per share.   Overall, we believe we are off to a strong start for 2011."

    "I am also very excited to have Dr. Jeffrey Litwin appointed as our new President and Chief Executive Officer as previously announced earlier today," continued Dr. Morganroth.  "Jeff and I have worked together for many years, and he brings knowledge of the clinical research domain that is our core business and also experience in the adjacent markets of Phase IV safety surveillance and healthcare."

    2011 Guidance The Company reaffirmed its previously-issued guidance for the full year of 2011.  ERT expects net revenues of between $178 million and $188 million for 2011.  ERT expects GAAP diluted net income per share to be between $0.30 and $0.40 for 2011 and non-GAAP diluted net income per share to be between $0.40 and $0.50 for the same period.   For the second quarter ending June 30, 2011, ERT expects net revenues of between $43.0 million and $46.0 million, GAAP diluted net income per share to be between $0.05 and $0.08 and non-GAAP diluted net income per share to be between $0.08 and $0.11.  

    Use of Non-GAAP Financial MeasuresIn addition to GAAP financial measures, ERT uses certain non-GAAP financial measures that exclude charges related to the amortization of the RS acquired intangible and other assets and acquisition and other costs which are related to the RS acquisition, and also their related income tax effects.  ERT believes that these non-GAAP measures are useful to investors because this supplemental information facilitates comparisons of its operations from period to period and to the performance of other companies within its industry and assists in gaining a better understanding of its operating results and future prospects.  ERT views amortization of acquired intangible and other assets related to the RS acquisition, which includes such items as the amortization of acquired customer backlog and technology, as items determined at the time of the acquisition.  While ERT reviews the underlying value of these intangibles regularly for impairment, the amortization is an expense typically not affected by operations during any particular period and does not contribute to the operational performance in any particular period.  ERT regards acquisition and other costs related to its recent acquisition as a cost that does not recur on a regular basis.  

    ERT's non-GAAP effective tax rates differ from its GAAP effective tax rates because of 1) the exclusion of the amortization of acquired intangible and other assets and acquisition and other costs incurred in 2010 related to its recent acquisition of RS, and 2) the income tax effect due to the difference between the GAAP and non-GAAP effective tax rate applied against the GAAP pre-tax income, primarily as a result of the acquisition costs incurred in 2010 not being deductible for income tax purposes.  ERT excludes the impact of these discrete tax items from its non-GAAP income tax provision because it believes they are not indicative of the effective income tax rate of its ongoing business operations.

    Management uses these non-GAAP financial measures, in addition to the measures prepared in accordance with GAAP, as the basis for measuring ERT's operating performance, financial and operating decision-making, development of budgets, and comparing such performance to that of prior periods for the same reasons stated above.  These non-GAAP financial measures are not meant to be considered superior to or a substitute for comparable financial measures prepared in accordance with GAAP.  There are also limitations on the non-GAAP measures, including: 1) these non-GAAP measures do not have standardized meanings and may not be comparable to similar non-GAAP measures used by other companies, 2) acquisition and other costs related to ERT's 2010 acquisition of RS represent actual cash expenditures that are excluded from ERT's non-GAAP measures, and 3) although amortization of acquired intangible and other assets does not directly impact ERT's current cash position, such expense is amortized over their expected economic lives and does represent the declining value of the assets acquired, but this expense is excluded from ERT's non-GAAP measures.  ERT adjusts for these limitations by relying on these non-GAAP measures only as a supplement to its GAAP results.

    Conference Call Dr. Morganroth, Dr. Litwin, and Mr. Keith Schneck, the Company's Chief Financial Officer, will hold a conference call to discuss these results.  The conference call will take place at 5:00 PM ET on May 2, 2011.  For the conference call, interested participants should dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 when calling internationally. There will be a playback available as well. To listen to the playback, please call 1-877-344-7529 when calling within the United States or 1-412-317-0088 when calling internationally.  Conference code for playback is 450262. This call is being webcast by MultiVu and can be accessed at ERT's website at www.ert.com. The webcast may also be accessed via the direct link at http://www.videonewswire.com/event.asp?id=78559. The webcast can be accessed for up to one year on either site.  

    About eResearchTechnology, Inc.ERT (www.ert.com) is a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations.  It is the market leader for centralized cardiac safety and respiratory efficacy services in drug development and also collects, analyzes and distributes electronic patient reported outcomes (ePRO) in multiple modalities across all phases of clinical research.

    This release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect our current views as to future events and financial performance with respect to our operations.  These statements can be identified by the fact that they do not relate strictly to historical or current facts.  They use words such as "aim," "anticipate," "are confident," "estimate," "expect," "will be," "will continue," "will likely result," "project," "intend," "plan," "believe," "look to" and other words and terms of similar meaning in conjunction with a discussion of future operating or financial performance.  

    These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements.  Factors that might cause such a difference include: unfavorable economic conditions; our ability to obtain new contracts and accurately estimate net revenues, our positive outlook for future bookings, variability in size, scope and duration of projects and internal issues at the sponsoring client; our ability to successfully integrate the RS or any future acquisitions; competitive factors in the market for our centralized services; changes in the bio-pharmaceutical and healthcare industries to which we sell our solutions; technological development; and market demand.  There is no guarantee that the amounts in our backlog will ever convert to revenue.  Should the economic conditions deteriorate, the cancellation rates that we have historically experienced could increase.  Further information on potential factors that could affect the Company's financial results can be found in ERT's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission.  Guidance is based on management's good faith expectations given current market conditions but that continued or further deterioration of general economic conditions, in addition to other factors cited elsewhere, could result in ERT not achieving the revenue and net income per diluted share guidance provided.

    Forward-looking statements speak only as of the date made.  We undertake no obligation to update any forward-looking statements, including prior forward-looking statements, to reflect the events or circumstances arising after the date as of which they were made.  As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements included in this release or that may be made in our filings with the Securities and Exchange Commission or elsewhere from time to time by, or on behalf of, us.Contact:Keith Schneck

    Robert EasteResearchTechnology, Inc.

    Westwicke Partners, LLC215-282-5566

    443-213-0502eResearchTechnology, Inc. and SubsidiariesConsolidated Statements of Operations(in thousands, except per share amounts)(unaudited)Three Months Ended March 31,20102011Net revenues:Services

    $
    4,835$
    23,977Site support

    7,03317,722Total net revenues

    21,86841,699Costs of revenues:Cost of services

    7,31113,156Cost of site support

    2,79910,123Total costs of revenues

    10,11023,279Gross margin

    11,75818,420Operating expenses:Selling and marketing

    3,4084,175General and administrative

    4,7457,508Research and development

    8581,383Total operating expenses

    9,01113,066Operating income

    2,7475,354Foreign exchange gains (losses)

    80(1,009)Other income (expense), net

    20(101)Income before income taxes

    2,8474,244Income tax provision

    1,0951,151Net income

    $
    ,752$
    3,093Net income per share:Basic

    $
    .04$
    .06Diluted

    $
    .04$
    .06Shares used in computing net income per share:Basic

    48,67548,896Diluted

    48,84549,251eResearchTechnology, Inc. and SubsidiariesConsolidated Balance Sheets(in thousands, except share and per share amounts)(unaudited)December 31, 2010

    March 31, 2011ASSETSCurrent assets:Cash and cash equivalents$
    30,343$
    29,614Short-term investments5050Investment in marketable securities6481,053Accounts receivable less allowance for doubtful accountsof $515 and $547, respectively37,23637,179Inventory4,6986,804Prepaid income taxes1,9882,660Prepaid expenses and other4,3935,531Deferred income taxes3,4313,431Total current assets82,78786,322Property and equipment, net42,61545,760Goodwill71,63776,702Intangible assets17,18717,435Other assets609718Total assets$
    214,835$
    226,937LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$
    7,136$
    ,613Accrued expenses16,16212,971Deferred revenues11,67012,657Total current liabilities34,96832,241Deferred rent2,3682,405Deferred income taxes3,7033,888Long-term debt21,00021,000Other liabilities2,1412,235Total liabilities64,18061,769Stockholders' equity:Preferred stock-$10.00 par value, 500,000 shares authorized,none issued and outstanding--Common stock-$.01 par value, 175,000,000 shares authorized,,460,782 and 60,661,086 shares issued, respectively605607Additional paid-in capital100,441101,438Accumulated other comprehensive (loss) income(1,545)8,922Retained earnings131,037134,130Treasury stock, 11,589,603 and 11,596,966 shares at cost (79,883)(79,929)Total stockholders' equity150,655165,168Total liabilities and stockholders' equity$
    214,835$
    226,937eResearchTechnology, Inc. and SubsidiariesConsolidated Statements of Cash Flows(in thousands)(unaudited)Three Months Ended March 31,20102011Operating activities:   Net income

    $
    ,752$
    3,093   Adjustments to reconcile net income to net cashprovided by operating activities:Depreciation and amortization

    2,6245,988Cost of sales of equipment

    13Share-based compensation

    605662Deferred income taxes

    (160)204Changes in operating assets and liabilities:Accounts receivable

    1,0331,030Inventory

    -(1,412)Prepaid expenses and other

    (1,341)(1,363)Accounts payable

    53991Accrued expenses

    920(3,191)Income taxes

    (193)(736)Deferred revenues

    (368)803Deferred rent

    (145)(164)Net cash provided by operating activities

    5,2675,008Investing activities:   Purchases of property and equipment

    (3,852)(7,254)   Purchases of investments

    (999)-   Proceeds from sales of investments

    3,716-   Payments for acquisitions

    (203)(117)Net cash used in investing activities

    (1,338)(7,371)Financing activities:   Proceeds from exercise of stock options

    51309   Stock option income tax benefit

    611   Repurchase of common stock for treasury

    -(46)Net cash provided by financing activities

    57274Effect of exchange rate changes on cash

    (790)1,360Net increase (decrease) in cash and cash equivalents

    3,196(729)Cash and cash equivalents, beginning of period

    68,97930,343Cash and cash equivalents, end of period

    $
    72,175$
    29,614eResearchTechnology, Inc. and SubsidiariesReconciliation of GAAP to Non-GAAP Information (in thousands, except per share amounts)(unaudited)Three Months EndedMarch 31, 2010

    December 31, 2010

    March 31, 2011Net revenues$
    21,868

    $
    44,900

    $
    41,699Reconciliation of GAAP to Non-GAAP gross margin:GAAP gross margin

    $
    ,758

    $
    9,708

    $
    8,420Amortization of acquired intangibles and other assets

    -

    2,288

    1,878Non-GAAP gross margin

    $
    ,758

    $
    21,996

    $
    20,298Non-GAAP gross margin percentage

    53.8%

    49.0%

    48.7%Non-GAAP gross margin percentage is calculated by dividing non-GAAP gross margin by net revenuesReconciliation of GAAP to Non-GAAPoperating income:GAAP operating income

    $
    2,747

    $
    5,230

    $
    5,354Amortization of acquired intangibles and other assets

    -

    2,288

    1,878Acquisition and integration related costs

    741

    800

    -Non-GAAP operating income

    $
    3,488

    $
    8,318

    $
    7,232Non-GAAP operating income margin percentage

    16.0%

    18.5%

    17.3%Non-GAAP operating income margin percentage is calculated by dividing non-GAAP operating income by net revenuesReconciliation of GAAP to Non-GAAP net income:GAAP net income

    $
    ,752

    $
    4,120

    $
    3,093Amortization of acquired intangibles and other assets

    -

    2,288

    1,878Acquisition and integration related costs

    741

    800

    -Income tax effect due to Non-GAAP reconciling items
    and other differences between the GAAP and
    Non-GAAP effective tax rate

    (284)

    (1,123)

    (502)Non-GAAP net income

    $
    2,209

    $
    ,085

    $
    4,469Reconciliation of GAAP to Non-GAAP diluted net income per share:GAAP diluted net income per share

    $
    .04

    $
    .08

    $
    .06Amortization of acquired intangibles and other assets

    -

    0.05

    0.04Acquisition and integration related costs

    0.02

    0.01

    -Income tax effect due to Non-GAAP reconciling items
    and other differences between the GAAP and
    Non-GAAP effective tax rate

    (0.01)

    (0.02)

    (0.01)Non-GAAP diluted net income per share

    $
    .05

    $
    .12

    $
    .09Shares used in computing diluted net income per share

    48,845

    49,274

    49,251Assumed effective tax rate - Non-GAAP

    35.0%

    29.0%

    27.0%Three MonthsEnding June 30, 2011Low RangeHigh RangeReconciliation of GAAP to Non-GAAPdiluted net income per share guidance:GAAP estimate of diluted net income per share

    $
    .05$
    .08Estimated effect on diluted net income per share of:Amortization of acquired intangibles and other assets

    0.040.04Income tax effect due to Non-GAAP reconciling items
    and other differences between the GAAP and
    Non-GAAP effective tax rate

    (0.01)(0.01)Non-GAAP estimate of diluted net income per share

    $
    .08$
    .11Shares used in computing estimated diluted net income per
    share

    49,50049,500Effective tax rate

    27.0%27.0%
    '/>"/>

    SOURCE ERT
    Copyright©2010 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    2. Spherix Reports Second Quarter Earnings
    3. Tapestry Reports Second Quarter 2007 Results
    4. Callisto Reports on Second-Quarter 2007 Milestones
    5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    9. Biopure Reports on Meeting with the FDA
    10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
    11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/11/2016)... --  Health 2.0 , the premiere showcase and catalyst ... " 10 Year Global Retrospective ", a platform to ... ten years.   --> ... served as the preeminent thought-leader in the health tech ... companies, innovators, and patient-activists through an array of events ...
    (Date:2/11/2016)... 2016  AfterPill.com is reporting that this week,s Centers ... all women who are at risk of unintended pregnancy ... and raises the risks of unprotected sex in particular.  ... According to the Guttmacher Institute, there are 43 million ... age, who have sex without the intention of becoming ...
    (Date:2/11/2016)... -- Transformational M&A achieved through NPS and Dyax ... Transformational M&A achieved through NPS and Dyax acquisitions and ... Transformational M&A achieved through NPS and Dyax acquisitions and the ... growth with most robust pipeline in Shire , ... with most robust pipeline in Shire , s ...
    Breaking Medicine Technology:
    (Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... article about foods choices that promote eye health. These articles generally list between ... Water and health advocate Sharon Kleyne endorses every one of these lists and ...
    (Date:2/12/2016)... Highlands Ranch, Colo. (PRWEB) , ... February 12, 2016 , ... ... particularly over the past 35 years. A president has access to health and wellness ... leader of the free world, no single individual has a schedule as frenetic as ...
    (Date:2/12/2016)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... are the real facts surrounding all those Bible stories. For generations families have gathered ... and Yisrayl says there is more to these than just mere “stories”. , ...
    (Date:2/12/2016)... Phoenix, AZ (PRWEB) , ... February 12, 2016 , ... ... Health Arizona General Hospital Emergency Room –Mesa. The new facility is licensed under ... Valley. , “Dr. Bingham is an excellent leader and will ensure our new ...
    (Date:2/11/2016)... ... 11, 2016 , ... SPH Analytics announced today that ... health solutions, MDinsight® and IndiGO®, for its primary care clinicians. The 3-year partnership ... the contract were not disclosed. , As the healthcare market moves towards quality-based ...
    Breaking Medicine News(10 mins):